Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older at the time of joining the study
• People whose general health and ability to carry out daily activities is rated as 0 or 1 on a standard oncology scale (meaning fully active or able to do light work)
• People diagnosed with a specific type of pancreatic cancer called pancreatic adenocarcinoma
• People whose pancreatic cancer cannot be surgically removed and is either confined to the local area or has spread to other parts of the body
• People who have not previously received chemotherapy for advanced or metastatic disease, or who had chemotherapy before surgery (adjuvant or neoadjuvant) as long as the cancer came back more than 12 months after that treatment ended; prior palliative radiotherapy is also accepted
• People whose health meets the requirements for receiving the chemotherapy combination called FOLFIRINOX, including no active heart disease, a normal heart rhythm reading (ECG), blood pressure that is not too high, and a negative pregnancy test where applicable
• People who have had a CT scan within the past 4 weeks showing at least one measurable area of cancer
• People who are well enough to attend all required appointments, treatments, and follow-up visits for the full duration of the study
• People whose blood test results, liver function, kidney function, and certain infection screening results fall within the ranges required by the trial
• People who have been fully informed about the trial and have signed a consent form
• People enrolled in a social security scheme (this is a French healthcare requirement — confirm with trial site)
• People who are willing and able to use effective contraception during the study

Who may not be able to join:

• People whose pancreatic cancer is of a type called neuroendocrine carcinoma or acinar cell carcinoma
• People who have had another cancer in the past 5 years or currently have another cancer, except for certain non-invasive skin or cervical conditions
• People who have cancer that has spread to the brain
• People whose estimated life expectancy is less than 3 months
• People who previously experienced a severe (grade 4) reaction to any of the chemotherapy drugs used in FOLFIRINOX during prior adjuvant or neoadjuvant treatment
• People who still have ongoing side effects above a mild level (grade 1) from previous chemotherapy
• People with a known serious allergy or sensitivity to any ingredient in the FOLFIRINOX treatment
• People currently taking part in another clinical drug trial, or who finished radiotherapy within 10 days before starting treatment
• People who carry certain genetic variations (in the DPYD or UGT1A1 genes) or have elevated levels of a substance called uracil in their blood, which can affect how the body processes chemotherapy drugs
• People who are pregnant or breastfeeding
• People who are unable to give informed consent or to participate fully in the trial due to geographical, social, or psychological reasons, including psychiatric conditions that affect understanding
• People who are under legal guardianship or a court-ordered protection arrangement

Important: Always verify eligibility with the trial site directly before applying.